All sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS18
PHASE 3 / 2-35
RECRUITING12
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO0%

Delay Index: of 8 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Mabwell (Shanghai) Bioscience Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
9MW1911
NCT06175351
P1/2Active, not recruitingModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)802025-09-30
9MW2821
NCT06947226
P1/2Not yet recruitingSolid Tumors1882026-04
9MW2821
NCT06823427
P2RecruitingUrothelial Carcinoma; Urothelial Carcinoma Bladder602026-06
9MW2821
NCT06492005
P2RecruitingTriple-Negative Breast Cancer1602026-07
9MW2821
NCT06196736
P3RecruitingAdvanced Urothelial Carcinoma4322026-09 (-4 mo)
9MW2921
NCT05990452
P1/2Active, not recruitingAdvanced Solid Tumor2612026-09-01
9MW3811 Injection
NCT07576608
P2RecruitingScar302026-12
9MW2821
NCT06079112
P1/2RecruitingAdvanced Urothelial Carcinoma1002026-12-31
9MW2821+other anticancer therapy
NCT06926998
P1/2Not yet recruitingGynecological Malignancies2602027-05-01
7MW4911
NCT07265622
P1/2RecruitingSolid Tumors2002027-07
7MW4911
NCT07216560
P1/2RecruitingGI Cancers2002027-07
9MW2821
NCT06592326
P3RecruitingUrothelial Carcinoma4602027-09
9MW2821
NCT07556848
P3Not yet recruitingLocally Advanced or Metastatic Triple-negative Breast Cancer3562027-12
9MW1911
NCT07292714
P2RecruitingChronic Obstructive Pulmonary Disease COPD3602027-12
9MW2821
NCT06692166
P3RecruitingCervical Cancer4202027-12-09
7MW3711
NCT07466160
P1/2RecruitingSolid Tumor2802027-12-31
9MW2821
NCT07314723
P2RecruitingUrothelial Carcinoma902027-12-31
7MW3711
NCT07831863
P3Not yet recruitingLung Squamous Cell Carcinoma6002029-03